Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals names Thomas Haughey chairman as Patrick Walsh steps down

Neutral Impact 3 of 5 leadership Written later

ANI Pharmaceuticals said Chairman Patrick Walsh has stepped down from the chair role and will not seek re-election at the 2026 Annual Meeting, remaining a director until then. The Board elected director Thomas Haughey as Chairman, and Jeanne Thoma replaced him as chair of the Audit and Finance Committee. The filing describes the change as a planned board transition, not one tied to any disagreement with the Board or management.

Key points

  • Patrick D. Walsh notified the company on November 24, 2025 that he will not seek re-election as a director at the 2026 Annual Meeting of Stockholders.
  • Thomas J. Haughey, a board member since May 2018, was unanimously elected Chairman of the Board.
  • Jeanne A. Thoma replaced Haughey as chair of the Audit and Finance Committee; Haughey remains a committee member.

The filing

CompanyANI Pharmaceuticals (ANIP)
Form8-K, current report
Filed with the SECDec 1, 2025, 6:58 AM ET
Accession number0001023024-25-000113

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:58 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 01, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.